Allergan Net Income 2006-2018 | AGN

Allergan annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Allergan net income for the quarter ending September 30, 2018 was $-0.038B, a 99.06% decline year-over-year.
  • Allergan net income for the twelve months ending September 30, 2018 was $2.209B, a 129.35% decline year-over-year.
  • Allergan annual net income for 2017 was $-4.404B, a 129.97% decline from 2016.
  • Allergan annual net income for 2016 was $14.695B, a 298.97% increase from 2015.
  • Allergan annual net income for 2015 was $3.683B, a 325.89% decline from 2014.
Allergan Annual Net Income
(Millions of US $)
2017 $-4,404
2016 $14,695
2015 $3,683
2014 $-1,631
2013 $-750
2012 $97
2011 $261
2010 $184
2009 $222
2008 $238
2007 $141
2006 $-445
2005 $139
Allergan Quarterly Net Income
(Millions of US $)
Q3 2018 $-38
Q2 2018 $-473
Q1 2018 $-333
Q4 2017 $3,052
Q3 2017 $-4,025
Q2 2017 $-796
Q1 2017 $-2,635
Q4 2016 $-70
Q3 2016 $15,150
Q2 2016 $-571
Q1 2016 $186
Q4 2015 $-701
Q3 2015 $5,232
Q2 2015 $-313
Q1 2015 $-535
Q4 2014 $-733
Q3 2014 $-1,043
Q2 2014 $49
Q1 2014 $97
Q4 2013 $-148
Q3 2013 $66
Q2 2013 $-565
Q1 2013 $-103
Q4 2012 $28
Q3 2012 $77
Q2 2012 $-62
Q1 2012 $55
Q4 2011 $95
Q3 2011 $68
Q2 2011 $53
Q1 2011 $45
Q4 2010 $18
Q3 2010 $26
Q2 2010 $71
Q1 2010 $70
Q4 2009 $57
Q3 2009 $63
Q2 2009 $53
Q1 2009 $49
Q4 2008 $56
Q3 2008 $71
Q2 2008 $60
Q1 2008 $51
Q4 2007 $38
Q3 2007 $35
Q2 2007 $36
Q1 2007 $32
Q4 2006 $-489
Q3 2006 $34
Q2 2006 $-16
Q1 2006 $25
Q4 2005 $20
Q3 2005 $39
Q2 2005 $40
Q1 2005 $39
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $50.030B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $17.948B 5.50
Mylan (MYL) United Kingdom $14.871B 6.12
Bausch Health Cos (BHC) Canada $7.541B 5.46
Dr Reddy's Laboratories (RDY) India $6.006B 23.95
Supernus Pharmaceuticals (SUPN) United States $1.872B 17.73
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.544B 2.57
Amphastar Pharmaceuticals (AMPH) United States $0.924B 100.20
Homology Medicines (FIXX) United States $0.889B 0.00
Assembly Biosciences (ASMB) United States $0.544B 0.00
Akorn (AKRX) United States $0.516B 0.00
CymaBay Therapeutics (CBAY) United States $0.480B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.373B 0.00
Voyager Therapeutics (VYGR) United States $0.319B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.240B 0.00
Sol-Gel Technologies (SLGL) Israel $0.115B 0.00
Teligent (TLGT) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.072B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.054B 0.00
Acasti Pharma (ACST) Canada $0.052B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.022B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.006B 0.00